Imap (Fluspirilene)

Fluspirilene works by competitively blocking dopamine D2 receptors in the brain. This antagonism reduces excessive dopaminergic activity in pathways that are associated with psychosis, thereby diminishing hallucinations, delusions and other core symptoms of schizophrenia.

The dose of Imap is determined by the prescribing clinician based on the individual’s clinical response, severity of illness and treatment history. Fluspirilene is administered as an intramuscular injection, and the frequency and amount are tailored to each patient’s needs.

Safety data for fluspirilene in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative therapies when appropriate.

To request Imap, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Imap (fluspirilene) belongs to the typical antipsychotic class, sharing a dopamine D2 antagonism mechanism with drugs such as haloperidol. Compared with many atypical agents, it may have a higher propensity for movement‑related side effects but offers a long duration of action that can reduce injection frequency, which may be advantageous for maintenance therapy.

Imap should be stored at 2‑8 °C in a refrigerator, protected from light. The vials must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper handling during transport.

Imap is given as an intramuscular injection, typically into the gluteal or deltoid muscle. Administration is performed by a qualified healthcare professional who follows aseptic technique and observes the recommended injection volume and site preparation.

The most serious adverse reactions to fluspirilene include tardive dyskinesia, which may be irreversible, neuroleptic malignant syndrome—a life‑threatening condition with fever, rigidity and autonomic instability, and severe hypotension that can cause fainting or shock. Patients should be monitored closely for these events.

Imap is contraindicated in individuals with known hypersensitivity to fluspirilene or any component of the formulation. It should also be avoided in patients with severe central nervous system depression, uncontrolled cardiovascular disease, or those taking medications that may cause dangerous interactions, unless a specialist advises otherwise.